BRPI0715690A2 - beta-agonistas enantiâmeros puros, processos para as suas preparaÇÕes e seu uso como medicamento - Google Patents

beta-agonistas enantiâmeros puros, processos para as suas preparaÇÕes e seu uso como medicamento

Info

Publication number
BRPI0715690A2
BRPI0715690A2 BRPI0715690-1A2A BRPI0715690A BRPI0715690A2 BR PI0715690 A2 BRPI0715690 A2 BR PI0715690A2 BR PI0715690 A BRPI0715690 A BR PI0715690A BR PI0715690 A2 BRPI0715690 A2 BR PI0715690A2
Authority
BR
Brazil
Prior art keywords
agonists
medicament
beta
processes
preparation
Prior art date
Application number
BRPI0715690-1A2A
Other languages
English (en)
Inventor
Ingo Konetzki
Peter Sieger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0715690A2 publication Critical patent/BRPI0715690A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0715690-1A2A 2006-08-22 2007-08-21 beta-agonistas enantiâmeros puros, processos para as suas preparaÇÕes e seu uso como medicamento BRPI0715690A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119273 2006-08-22
PCT/EP2007/058654 WO2008023004A1 (de) 2006-08-22 2007-08-21 Enantiomerenreine betaagonisten, verfahren zu deren herstellungen und deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0715690A2 true BRPI0715690A2 (pt) 2013-09-17

Family

ID=38698758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715690-1A2A BRPI0715690A2 (pt) 2006-08-22 2007-08-21 beta-agonistas enantiâmeros puros, processos para as suas preparaÇÕes e seu uso como medicamento

Country Status (22)

Country Link
US (1) US7709474B2 (pt)
EP (1) EP2057134A1 (pt)
JP (1) JP2010501522A (pt)
KR (1) KR20090043586A (pt)
CN (1) CN101506182A (pt)
AR (1) AR062476A1 (pt)
AU (1) AU2007287537A1 (pt)
BR (1) BRPI0715690A2 (pt)
CA (1) CA2661143A1 (pt)
CO (1) CO6150169A2 (pt)
EA (1) EA200900268A1 (pt)
EC (1) ECSP099082A (pt)
IL (1) IL197124A0 (pt)
MX (1) MX2009001515A (pt)
NO (1) NO20090101L (pt)
NZ (1) NZ575567A (pt)
PE (1) PE20080610A1 (pt)
TW (1) TW200817347A (pt)
UA (1) UA96951C2 (pt)
UY (1) UY30550A1 (pt)
WO (1) WO2008023004A1 (pt)
ZA (1) ZA200810829B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056836A1 (en) * 2006-08-22 2009-05-13 Boehringer Ingelheim International GmbH Powder formulations for inhalation containing enantiomerically pure beta-agonists
PE20080425A1 (es) * 2006-08-22 2008-06-16 Boehringer Ingelheim Int Formulacion aerosol para la inhalacion de beta-agonistas
AU2008261261B2 (en) 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026534A1 (de) * 1980-07-12 1982-03-18 C.H. Boehringer Sohn, 6507 Ingelheim 3,1-benzoxazin-2-one, ihre herstellung und verwendung
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
DE3609152A1 (de) 1986-03-19 1987-09-24 Bayer Ag Verfahren zur herstellung des (-)-antipoden des (e)-1-cyclohexyl-4,4-dimethyl- 3-hydroxy-2-(1,2,4-triazol-1-yl)-pent-1-ens
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
US5495054A (en) 1994-05-31 1996-02-27 Sepracor, Inc. Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
DE19536903C2 (de) 1995-10-04 1998-09-10 Boehringer Ingelheim Int Vorrichtung zum Haltern eines fluidischen Bauteils
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19545226C1 (de) 1995-12-05 1997-06-19 Boehringer Ingelheim Int Sperrspannwerk für einen federbetätigten Abtrieb
DE19742439C1 (de) 1997-09-26 1998-10-22 Boehringer Ingelheim Int Mikrostrukturiertes Filter
DE50103666D1 (de) 2000-10-12 2004-10-21 Boehringer Ingelheim Pharma Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
DE10203749A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU2004226824B2 (en) 2003-04-04 2008-05-01 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005008921A1 (de) 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
UY30552A1 (es) 2006-08-22 2008-03-31 Boehringer Ingelheim Int Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
PE20080425A1 (es) 2006-08-22 2008-06-16 Boehringer Ingelheim Int Formulacion aerosol para la inhalacion de beta-agonistas

Also Published As

Publication number Publication date
WO2008023004A1 (de) 2008-02-28
UY30550A1 (es) 2008-03-31
US7709474B2 (en) 2010-05-04
JP2010501522A (ja) 2010-01-21
WO2008023004A8 (de) 2008-05-22
EP2057134A1 (de) 2009-05-13
US20080070909A1 (en) 2008-03-20
NZ575567A (en) 2011-12-22
CN101506182A (zh) 2009-08-12
IL197124A0 (en) 2009-11-18
AU2007287537A1 (en) 2008-02-28
AR062476A1 (es) 2008-11-12
CA2661143A1 (en) 2008-02-28
KR20090043586A (ko) 2009-05-06
UA96951C2 (ru) 2011-12-26
EA200900268A1 (ru) 2009-08-28
ECSP099082A (es) 2009-02-27
NO20090101L (no) 2009-01-29
CO6150169A2 (es) 2010-04-20
TW200817347A (en) 2008-04-16
PE20080610A1 (es) 2008-07-15
MX2009001515A (es) 2009-02-18
ZA200810829B (en) 2009-11-25

Similar Documents

Publication Publication Date Title
BRPI0817198A2 (pt) (ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
ZA201007679B (en) Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup,processes for their preparation and their use as pharmaceuticals
BRPI0907036A2 (pt) Conjunto de máscara para fornecer gás para um paciente, e, kit de conjunto de máscara para fornecer um gás para um paciente.
BRPI0921802A8 (pt) uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0924427A2 (pt) composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
BRPI0810882A2 (pt) Derivados de ftalazinona e seu uso como medicamento para tratar câncer
BRPI0912581A2 (pt) látex catiônico como um veículo para ingredientes ativos e métodos para preparar e usar o mesmo
ZA200805939B (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL196008A0 (en) Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
BRPI0909625A2 (pt) agonista seletivo do receptor s1p1 para o uso como um medicamento, uso do mesmo e kit que contém diferentes unidades de medicação de um agonista seletivo do receptor s1p1
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0719523A2 (pt) Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
CO6870037A2 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0818483A2 (pt) Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
BRPI0821915A2 (pt) Piridil-n-(1,3,4)-tiadiazol-2-il-benzeno sulfonamidas cíclicas, processos para sua preparação e seu uso como produtos farmacêuticos
BRPI1011412A2 (pt) composição para liberação sustentada de droga compreendendo alutinante geopolimérico
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
BRPI1015943A2 (pt) derivados de 1,2,3,4-tetra - hidro - pirimido [1,2-a] pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
BR112014007568A2 (pt) composição farmacêutica, uso e processo para preparar a mesma
BRPI1014125A2 (pt) composto, composição farmacêutica, e, uso de um composto.

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.